What Panic Disorder Actually Is

A panic attack is not a bad day of anxiety. It is a sudden, uninvited surge of terror that peaks within minutes and hijacks the entire body. Heart hammering. Chest tight. Hands tingling. A sense of unreality, like the world has shifted slightly off its axis. Many people having their first panic attack go to the emergency room convinced they are having a heart attack or a stroke. The ER workup comes back clean, and they go home with a discharge summary that says “anxiety.”

Panic disorder is what happens when these episodes keep coming back and the fear of the next one starts dictating your decisions. You stop driving on highways because you once had an attack on I-65. You avoid crowded stores. You sit on the aisle at restaurants so you can leave quickly. You begin scanning your body for the early warning signs—a slight acceleration of heartbeat, a flutter of dizziness—and the scanning itself becomes a trigger. The fear of panic produces panic.

Roughly 2.7% of American adults have panic disorder in any given year, according to the National Institute of Mental Health. It is twice as common in women. It tends to begin in the late teens or early twenties, and without adequate treatment, it frequently becomes chronic. About one-third of people with panic disorder develop agoraphobia—avoidance of situations where escape would be difficult if an attack struck—which can narrow a person’s life to an increasingly small radius.

The Neurobiology of Panic

Panic attacks originate in a specific brain circuit, distinct from the circuitry involved in generalized worry. Understanding this circuit helps explain why ketamine’s mechanism might matter here.

The core of the panic circuit involves three structures:

A 2025 review in Advances in Psychiatry described this as a breakdown in the brain’s fear circuitry: the threat detection system fires too easily, the escalation system amplifies the signal too aggressively, and the regulatory system cannot shut it down. The person experiences a full-body emergency response to a threat that does not exist outside their own nervous system.

There is also a glutamatergic component. Research has found elevated glutamate levels in the fear circuitry of patients with panic disorder, and NMDA receptor dysfunction has been implicated in the persistence of fear memories that maintain the condition. This is relevant because ketamine acts directly on NMDA receptors.

Why Standard Treatments Leave People Stuck

The first-line treatments for panic disorder are SSRIs and cognitive behavioral therapy, specifically a protocol involving exposure to feared bodily sensations (interoceptive exposure) and feared situations. Both work. The problem is that “work” has limits.

SSRIs help about half of patients reach remission. The other half improve partially or not at all. And SSRIs take 4 to 8 weeks to reach full effect for panic disorder, during which the anxiety often worsens before it improves—a paradox that is particularly cruel for someone already terrified of their own fear response.

Benzodiazepines provide rapid relief. A 0.5 mg dose of alprazolam can abort a panic attack within 20 minutes. But long-term benzodiazepine use carries real risks: physical dependence, cognitive impairment, rebound anxiety on discontinuation, and interference with the learning processes that make exposure therapy effective. Most guidelines recommend against ongoing benzodiazepine use for panic disorder.

CBT with interoceptive exposure has the strongest evidence base, with response rates around 60 to 80 percent in clinical trials. But access is a constraint. Finding a therapist trained in exposure-based CBT for panic, with availability, in your area, at a price you can afford, is a meaningful barrier. And for the 20 to 40 percent who do not respond adequately to CBT, the remaining options are limited: medication switches, augmentation strategies, or continued suffering.

For patients in this gap—those who have tried SSRIs, possibly a second or third medication, attempted therapy, and still cannot drive to work without gripping the steering wheel and scanning for the first sign of an attack—the question of what else exists is not academic. It is urgent.

What the Research Shows

The evidence for ketamine in panic disorder specifically is early but growing, and it comes from three categories of research.

The case report. A case published in Primary Care Companion for CNS Disorders documented a patient with treatment-refractory panic disorder, agoraphobia, and generalized anxiety disorder who experienced sustained resolution of all three conditions following a single IV ketamine infusion at standard dosing (0.5 mg/kg over 40 minutes). The patient had failed multiple medication trials. After ketamine, the panic attacks stopped, the agoraphobia remitted, and the improvement persisted. One case does not prove efficacy, but it demonstrates biological plausibility and warranted further investigation.

The systematic reviews. In 2025, Masdrakis and colleagues published a systematic review in the Journal of Psychopharmacology examining ketamine and esketamine treatment protocols across anxiety disorders, including panic disorder, GAD, social anxiety, PTSD, and OCD. Their conclusion: ketamine demonstrates anxiolytic effects across anxiety disorder subtypes, with effects that can be sustained through repeated dosing. The anxiolytic effect appeared to operate independently of the antidepressant effect, suggesting ketamine addresses anxiety through its own distinct mechanism rather than simply reducing depression that co-occurs with anxiety.

The meta-analysis. A meta-analysis of randomized controlled trials published in Therapeutic Advances in Psychopharmacology found that ketamine reduced panic and irritability ratings within 24 hours of infusion, with higher doses producing more robust effects. Anxiolytic effects lasted approximately one to two weeks following a single dose. This timeframe aligns with the neuroplastic window—the period of enhanced synaptic flexibility following ketamine treatment.

None of this constitutes the kind of large, multi-site randomized controlled trial that would make the evidence definitive. That trial has not been conducted for panic disorder specifically. But the direction is consistent across study types, and it aligns with what we understand about ketamine’s mechanism of action.

How Ketamine Addresses the Panic Circuit

Ketamine’s mechanism is relevant to panic disorder at multiple levels of the fear circuit.

NMDA receptor blockade reduces glutamatergic hyperactivity. The excessive glutamate signaling in the amygdala and prefrontal cortex that drives panic may be dampened by ketamine’s action as an NMDA antagonist. This does not eliminate the fear circuit; it reduces the volume on a system that has been turned up too high.

Rapid synaptogenesis strengthens prefrontal regulation. Ketamine triggers a cascade involving BDNF release and mTOR signaling that promotes the growth of new synaptic connections in the prefrontal cortex. Stronger prefrontal connections mean better top-down control of the amygdala. The regulatory system that was failing during panic attacks becomes more capable of sending the “stand down” signal.

Enhanced plasticity may allow fear memory revision. Panic disorder is maintained partly by learned associations: the body learns to associate certain internal sensations or external situations with danger, and those associations become consolidated in memory. The neuroplastic window following ketamine creates a period in which the brain is more receptive to revising old associations. If a patient practices exposure—deliberately entering situations they have been avoiding or tolerating feared bodily sensations—during this window, the corrective learning may consolidate more effectively.

Panic Disorder Is Not Just “Bad Anxiety”

We have written about ketamine for anxiety and ketamine for social anxiety elsewhere on this blog. Panic disorder deserves its own discussion because the experience and neurobiology are distinct.

Generalized anxiety is a slow burn. It is constant low-grade dread spread across many domains of life. Social anxiety is tied specifically to evaluation by others. Panic disorder is an acute event—a sudden, overwhelming physiological storm that appears to come from nowhere, peaks in minutes, and leaves the person exhausted and afraid of its return.

The fear in panic disorder is often interoceptive: directed at the body’s own signals. A person with generalized anxiety worries about work, finances, relationships. A person with panic disorder worries about their heart rate, their breathing, their dizziness. The body becomes the threat. This creates a particularly isolating experience because the danger feels internal and inescapable.

When panic disorder leads to agoraphobia, the restriction compounds. A person who has had attacks in grocery stores, on highways, in meetings, and at family gatherings eventually runs out of “safe” places. Home becomes the last reliable refuge, and even home sometimes stops feeling safe. The world gets very small.

What Treatment Looks Like at Our Clinic

At Music City Ketamine, we treat panic disorder as part of our anxiety protocol. During your initial consultation, we discuss the pattern of your attacks: how often they occur, what situations or sensations trigger them, how much avoidance has accumulated, what medications you have tried, and whether you also carry depression, PTSD, or other conditions alongside the panic. Many of our patients have more than one diagnosis, and we consider the full picture.

Marla Peterson, CRNA, administers and oversees every infusion. The protocol follows the standard 0.5 mg/kg dosing over 40 minutes, consistent with the clinical research. We typically start with a series of six infusions over two to three weeks.

What patients with panic disorder often notice first is not the absence of attacks but a change in their relationship to the physical sensations that used to set off the cascade. A slight acceleration of heartbeat does not immediately spiral into catastrophe. There is a moment of space between the sensation and the fear, and that space—even when it is small—represents a meaningful shift in how the nervous system is processing threat.

Walter White and Wilma, our therapy dogs, are present during sessions. For patients whose nervous systems have been on high alert, the calm presence of a dog who is entirely unbothered by the world can be grounding in a way that words are not.

We encourage patients to work with a therapist trained in exposure-based CBT, particularly during the neuroplastic window following each infusion. The combination of pharmacological support (ketamine reducing amygdala hyperreactivity) and behavioral exposure (generating corrective learning about feared situations and sensations) may be more effective than either approach alone. We can help connect you with a therapist if you do not already have one.

For patients in the Franklin, Nashville, Brentwood, Cool Springs, and Middle Tennessee area, our clinic is at 480 Duke Dr., Suite #100 in Franklin. Information about pricing is available on our website.